NCT03017573Recruiting
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
Source: ClinicalTrials.gov · Last updated 3 Feb 2026
Brief summary (registry, in English)
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer and sarcoma (breast angiosarcoma and uterine sarcoma) cancers. This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1050 (estimated)
- First submitted
- 9 Jan 2017
- Start date
- 6 Jan 2017
- Primary completion date
- 6 Aug 2029
- Lead sponsor
- Institut Curie
- Diseases
- Triple-negative breast cancer, Head and neck cancer, Cervical cancer, Ovarian cancer, Sarcoma
- NCT number
- NCT03017573
What you commit to
- Study type: Interventional
- Planned participants: 1050
- From 6 Jan 2017 to the primary completion date, 6 Aug 2029
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Age
- Male or female patients ≤18 years old
Other
- Individually deprived of liberty or placed under the authority of a tutor
- Patients not affiliated to the Social Security System
Who the study is looking for
- Tumor types :
- Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or neoadjuvant chemotherapy
- Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy
- Newly diagnosed treatment-naïve head and neck cancer patients eligible for surgery
- Newly diagnosed treatment-naïve vulva cancer (all types) or cervical cancer patients with (1) stage Ia - IIa1 with nodal metastasis, postoperative positive margin or parametrial-vaginal involvement, and (2) stage ≥IIa2).
- Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcoma or (2) uterine sarcoma eligible for surgery or systemic treatment
- Male or female patients ≥ 18 years of age
- Signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Bergonie Coordinator of this site? Confirm its status | Bordeaux | France | Recruiting |
| Centre Oscar Lambret Coordinator of this site? Confirm its status | Lille | France | Recruiting |
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| Institut Curie - Hôpital René Huguenin Coordinator of this site? Confirm its status | Saint-Cloud | France | Recruiting |
| Institut de Cancérologie de Lorraine - Nancy Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.